Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CYCC 2.31 all out of trade. 2.30s my target
CYCC 2.19 unloaded 80% so far now hold 20% for potential 2.30s
CYCC 2.06 let’s see if we get to 2.30s
CYCC 1.96 must hold at least 1.92 for me and if breaks 2.03 then 2.05- 2.37 next zone of interest
No offering…The Company has determined not to pursue, at this time, the public offering to which the Registration Statement relates. The Registration Statement has not been declared effective by the Commission and no securities have been issued or sold under the Registration Statement. Accordingly, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477.
The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, the Company respectfully requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account to be offset against the filing fee for any future registration statement or registration statements.
CYCC 2.03 scale out a little more
CYCC 1.91 scale out now
CYCC 1.36- 1.78
CYCC hit it low floater ….news The Company has determined not to pursue, at this time, the public offering to which the Registration Statement relates. The Registration Statement has not been declared effective by the Commission and no securities have been issued or sold under the Registration Statement. Accordingly, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477.
The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, the Company respectfully requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account to be offset against the filing fee for any future registration statement or registration statements.
At $7 now MULN lol it’s a short term play on EVs made in the USA by a saintly CEO and then run away from the trade. $8- $9.13 is the next level extreme high risk buyer beware
Got some EFTR nice small floater. Get ready for Yellen to blow up the markets soon they need rate cuts for votes and housing market. Only temporary rate cuts until elections.
CLDI .25 + 68% offering at .40 cents nice pump
No more no buy now WBUY .32 bottom in
Lets get a morning GRRR $4.91 bottom in
GRRR bottom in
Yellen about to do a major market pump by forcing rates down temporarily before elections….politics politics….The US Treasury's Quarterly Refunding Announcement (QRA) on how much issuance will be made has become important due to emerging concerns of developing supply/demand mismatch for longer
Markets soaring next week !!! Yellens announcement Monday or at latest Wednesday about a massive bond short squeeze they need rates down now and quickly before elections to make people stop thinking everything is expensive.
The bet still on for interest rate cut lol
LIFW .99 +5% in some …market correction stagflation looking lows don’t last long
BDRX Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the
Treatment of Familial Adenomatous Polyposis (FAP)
Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP
An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum
PEGY IVP
Pineapple HoldingsPEGY
0.0899 +73.22% 35.56M
Inspire Veterinary.IVP
0.0467 +22.57% 2.42M
Jump jump
BCSAU $19 +68% TVGN FRGT PEGY ELWS NIVF
Blockchain Coinves.BCSAU
19.00 +68.89% 78.38K
Tevogen Bio Holdin.TVGN
1.35 +58.82% 1.32M
Freight TechFRGT
1.25 +36.76% 3.73M
Pineapple HoldingsPEGY
0.071 +36.80% 17
“Today we present initial clinical data from our ongoing Phase 2 clinical trial which we believe highlights the power of our next generation proteomics-based AP3 precision medicine platform,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. “For the first time, we share statistically significant prospective validation of our AP3 patient selection approach via our ACR-368 OncoSignature assay, which demonstrated the ability to effectively identify cancer patients whose tumors are likely to respond to ACR-368 monotherapy treatment. We are extremely gratified to not only confirm the ability to identify and enrich for patient responders with ovarian cancer, but also for patients with endometrial cancer, a new tumor type identified and predicted to be sensitive to ACR-368 by our AP3 platform prior to clinical trial initiation.”
“Today’s R&D event provides us an opportunity to present the compelling preclinical data of our AP3-based, rationally-designed ACR-2316 dual WEE1/PKMYT1 inhibitor,” said Kristina Masson, Ph.D., M.B.A., co-founder and executive vice president of business operations at Acrivon Therapeutics, Inc. and president and CEO of the company´s research subsidiary Acrivon AB. “We are excited to announce our accelerated timelines for IND filing, now expected in the third quarter with potential clinical study initiation now anticipated in the fourth quarter of this year. We believe this potential first-in-class asset, which is specifically designed for superior single-agent activity as demonstrated in preclinical studies against benchmark inhibitors, has the potential to address significant unmet treatment needs against a broad range of tumors in patients with limited treatment options.”
Company Provides Program and Data Highlights:
An overview of the broad, actionable scientific capabilities and clinically demonstrated deliverables of the AP3 platform
Initial ACR-368 clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) in the ongoing registrational-intent Phase 2b trial are being presented (data cut as of April 1, 2024).
A confirmed ORR (per RECIST 1.1) of 50% was observed in the prospective cohort of OncoSignature-positive patients who were efficacy-evaluable. All confirmed responders continue to be on treatment, median duration of response (DoR) has not yet been reached. Notably, endometrial cancer is a new tumor type with significant unmet medical need that was identified and predicted to be sensitive to ACR-368 by AP3 indication screening.
Initial, prospective validation of the AP3-based ACR-368 OncoSignature assay demonstrating its ability to identify ovarian and endometrial patients sensitive to ACR-368 monotherapy in the ongoing clinical trial, with clear segregation of RECIST responders in the OncoSignature-positive (50% confirmed ORR in 10 patients) versus OncoSignature-negative (0% ORR in 16 patients) arms (p-value=0.0038).
In the OncoSignature-negative arm with ovarian or endometrial cancers, encouraging signs of clinical activity were observed in response to ACR-368 with ultra-low dose gemcitabine at the recommended Phase 2 combination dose, with 8 out of 16 patients achieving stable disease.
Consistent with past trials, the ACR-368 treatment-related adverse event profile was predominantly reversible and transient with only mechanism-based, hematological adverse events.
ACR-2316, a potential first-in-class, potent WEE1/PKMYT1 inhibitor continues to advance rapidly with IND filing now expected in Q3 2024 (vs. previous guidance of Q4 2024) and the initiation of a clinical trial is anticipated in Q4 2024. ACR-2316 is uniquely designed by AP3 for superior single-agent activity and to overcome limitations of current WEE1 inhibitors and PKMYT1 inhibitors.
A preview of the AP3 Interactome, which is a proprietary, machine-learning-enabled interactive platform used to uncover actionable drug-induced pathway effects across all studies.
A live and recorded webcast of the event will be available through a link on the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations. The webcast will be available for at least 30 days following the event.
ACRV $12 + 27% look for $12.10- $14.09
ILAG .77 start taking your money cash time
Not lagging for now
ILAG .70 look at .81-.89 zone to book profits first resistance to beat .68-.72 doesn’t go clear the deck
I don’t lag for now ILAG .67 + 25-%
AIRE plenty of resistance 1.13-1.21 so that’s a sell zone then 1.22- 1.37
CGC 9.21
DJT $35.38 …. 12:31 PM EDT, 04/24/2024 (MT Newswires) -- Trump Media & Technology Group (DJT) CEO Devin Nunes penned a letter to the Republican heads of various committees in the US House of Representatives, urging them to investigate the possible manipulation of the company's stock.
"Overall, we assess there are strong indications of unlawful manipulation of [Trump Media & Technology] stock," Nunes said in the letter. "As such, I respectfully request that you open an investigation of anomalous trading of [Trump Media & Technology] to determine its extent and purpose, and whether any laws, including RICO statues and tax evasion laws, were violated, so that perpetrators of any illegal activity can be held to account."
WHLM $6.97 Push it higher 33k float lol
Push it higher 33k float lol
CZOO MULN look at resistance levels and take profits quickly anything that’s automaker in big trouble as Banks not issuing auto loans anymore except for perfect credit scores..
1.92 NKGN added 1.60s earlier for the next run break 1.95- 1.97 and then 2.32-2.56 zone looks juicy
TROO 1.68 take those profits time hit the zone
TPST 3.48 look at 3.72- 3.99 for next zone and a solid break above 3.99 and sparkles could come..
GRRR 5.47 hold above 5.35 then join the moon market crew for another round 6.40- 6.92
CDIO .79 +5% added some .78 assuming.75 holds then look for $1 as next stop down the road
TROO 1.36 + 26% solid break above 1.38 then next sell zone from 1.60- 1.99. Doesn’t hold above 1.38 then scale out
AMST 3.63 next zone to watch 3.72- 4.18 2m float above 4.18 then 4.35 to watch
CYTO 1.82 + 15% 2m floater .. Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal
Study met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013)
Corroborated by statistically significant improvement in health-related quality of life and reduced need for relief medication
Study outcomes support plans for further international expansion
HAMILTON, BERMUDA -- April 24, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the publication of the detailed results from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR). The peer-reviewed article appeared in Allergy,1 which is published by the European Academy of Allergy and Clinical Immunology and recognizes as one of the highest-ranking journals in the field of allergology. Bentrio (AM-301) is a drug-free and preservative-free nasal spray designed to help protect against airborne allergens such as pollen or house dust mites.
The NASAR trial enrolled 100 patients during two allergy seasons in Australia who were randomized at a 1:1 ratio to receive either Bentrio or saline nasal spray, the current standard of care in drug-free SAR management. Study participants self-administered the treatment for two weeks three times per day. The primary efficacy endpoint was the reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS; ANCOVA model).
Bentrio-treated patients achieved a significantly lower rTNSS than the saline group (least square means difference -1.1, p = 0.013) with improvement observed across all individual nasal symptoms. Health-related quality of life, as measured by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), was significantly improved as well (p < 0.001). Patients and investigators rated the efficacy of treatment as significantly better with Bentrio compared to saline control (both p < 0.001). Both treatments showed similarly good safety and tolerability. With Bentrio, fewer patients used relief medication and more enjoyed symptom-free days compared to saline treatment.
“We are thrilled to see the detailed results from our pivotal Australian trial published in one the leading medical journals in allergology,” commented Thomas Meyer, Altamira’s founder, Chairman, and CEO. “The study provided a wealth of additional evidence for the protective effects of Bentrio as well as its good safety and tolerability. In addition, we are very encouraged to see that Bentrio helps to manage not only mild allergy symptoms, but also more severe ones, and appears to reduce the need for the use of drug-based relief treatments. We would like to thank all participating patients and study sites for their contributions to the NASAR trial and look forward to making Bentrio available in additional countries and helping patients who have to deal with the daily burden and discomfort associated with allergic rhinitis.”
Bentrio is marketed by Altamira Medica AG, an associate company of Altamira Therapeutics, primarily through distributors. From 2024 onwards, Altamira Medica expects sales to grow significantly, mainly driven by the launch of Bentrio in additional countries. The Company expects to conclude partnering discussions and negotiations for distribution in the US, Europe and other key markets in the course of 2024